MARLBOROUGH, Mass.– Hologic Inc. has completed its acquisition by investment firms Blackstone and TPG, taking the women’s health-focused medical technology company private in a deal valued at up to $79 per share.
The transaction, first announced in October 2025 and approved by shareholders in February 2026, includes minority investments from affiliates of the Abu Dhabi Investment Authority and GIC.
As part of the deal’s closing, Hologic named José (Joe) E. Almeida as chief executive officer, effective immediately. Almeida succeeds Stephen MacMillan, who recently retired after more than a decade leading the company.
“Hologic is an incredible company with a storied history of innovation and an unparalleled reputation as a leader in women’s health,” Almeida said. “I am thrilled to be joining at such a pivotal moment. With the backing of Blackstone and TPG, we are poised to take the organization to new heights, with a renewed sense of purpose and greater resources to invest in innovation and initiatives that will advance the mission of enabling healthier lives around the world.”
Under the terms of the transaction, Hologic shareholders will receive $76 per share in cash, along with a non-tradable contingent value right that could deliver up to an additional $3 per share based on the company’s breast health business meeting certain revenue targets in fiscal 2026 and 2027.
Blackstone and TPG said the deal positions Hologic for its next phase of growth as a private company, with increased flexibility to invest in innovation.
“Hologic has established itself as a global leader in advancing women’s health, with a proven track record of delivering life-changing medical technologies. We are thrilled to partner with Joe Almeida — an exceptional medical technology leader — alongside Hologic’s talented team and TPG to drive the company’s next phase of growth and innovation,” said Ram Jagannath, senior managing director and global head of healthcare at Blackstone.
“Hologic’s mission is to advance detection and care to improve health outcomes for women worldwide,” said Alex Albert, partner at TPG and co-head of healthcare for TPG Capital. “Investing behind healthcare innovation has been a core thematic focus for TPG over decades, and we have long admired Hologic as an industry leader. Under Joe’s experienced and proven leadership, we are proud to partner with Hologic and Blackstone to support clinical excellence and deliver meaningful impact for patients.”
Almeida most recently served as chairman, president, and CEO of Baxter International Inc. from 2016 to early 2025, where he led a strategic repositioning focused on operational improvements and portfolio transformation. He previously held senior leadership roles at Covidien plc, Tyco Healthcare, and Johnson & Johnson divisions.
Following the completion of the transaction, Hologic’s common stock has been delisted from the Nasdaq Stock Market.
